Regeneron Pharmaceuticals, Inc...

NASDAQ: REGN
$739.54
+$4.41 (+0.6%)
Closing price October 4, 2022
Monday's top analyst upgrades and downgrades included American Express, AT&T, CRISPR Therapeutics, DocuSign, ONEOK, Regeneron Pharmaceuticals, Shopify and Tesla.
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
As an approved COVID-19 vaccine nears completion in terms of clinical trials, what can we expect? In the past couple of weeks, firms working toward this goal have taken steps forward and back, which...
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
After Friday's close, two very high-profile stock splits are taking place. 24/7 Wall St. thinks there are some other stocks that could and should split their shares in their wake.
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Thursday's top analyst upgrades and downgrades included BioMarin Pharmaceuticals, Checkpoint Software Technologies, Cinemark, Fortinet, Palo Alto Networks, Regeneron Pharmaceuticals, Shake Shack,...
After two very high-profile stock splits, the time is ripe for many other well-known, actively traded stocks to announce stock splits. We have some ideas who might be next.
Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.
Regeneron Pharmaceuticals, one of the front-runners for the development of a COVID-19 treatment, released an update on its antibody drug combination on Monday.
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see a big...
Thursday's top analyst upgrades and downgrades included Alibaba, Bank of America, Beyond Meat, Chipotle Mexican Grill, First Solar, Microsoft, Plug Power, Square, Tesla and Valero Energy.